Timely by DrFirst launched a tool to streamline prior authorizations and improve access to specialty medications.

The post Timely by DrFirst Aims to Lower Barriers to Specialty Meds appeared first on MedCity News.

[Sponsored] Nicole Bulochnik, Abarca Senior Vice President of Drug Value Strategy, explained how AI, analytics, and cross-sector collaboration can transform specialty drug costs.

The post How AI, Analytics, and Collaboration Can Solve Specialty Drug Spending Challenges appeared first on MedCity News.

Free Market Health acquired Beeline Rx, a tech company that streamlines the prior authorization process for specialty drugs.

The post Free Market Health Acquires Beeline Rx to Streamline Specialty Prior Auth appeared first on MedCity News.

We can no longer simply worry about the enrollment form as the only hurdle in therapy initiation. We must view the entire patient journey as an interconnected set of challenges that need solving. And I believe achieving that goal is within reach.

The post What Drives Specialty Medication Enrollment Conversions? It’s Not What You Think. appeared first on MedCity News.

Hospitals’ pharmacy spending is projected to rise by 3.42% next year, according to a new report. Specialty drugs, including Ozempic and Humira, as well as neurology medications are the primary drivers of this increase in pharmacy expenses.

The post Which Drugs Are Driving Next Year’s 3.42% Increase in Hospital Pharmacy Spend? appeared first on MedCity News.

Lyfegen, a startup that provides software for value-based drug contracting, recently raised $8 million in an oversubscribed Series A financing round. With the new funds, the company — which is based in Switzerland and New York — plans to expand its presence in the U.S., where drug costs are the highest in the world.

The post Lyfegen raises $8M for its value-based drug contracting platform appeared first on MedCity News.

In recent years, a number of niche vendors have entered the market, promising significant savings for payers if they “carve-out” specialty pharmacy services from integrated pharmacy benefits management (PBM). While the savings they claim to provide sound undeniably attractive, they are often greatly exaggerated.

The post Inflated savings, hidden costs: How vendors who “carve-out” specialty benefits fail to deliver promised value appeared first on MedCity News.

Adam Schechter, an adviser to Merck’s CEO, said at the Veeva Summit Tuesday that many primary care diseases – such as cardiovascular disease and Alzheimer’s – still have significant unmet needs.

The post Focus on specialty drugs reflects ‘cyclical nature’ of biopharma, industry veteran says appeared first on MedCity News.

The post PwC Infographic: Costs from specialty drugs skyrocket appeared first on MedCity News.

The post Specialty drugs are driving up the U.S. medication spend – indeed a prime revenue opp appeared first on MedCity News.

The post The economics of high-cost specialty drugs, illustrated appeared first on MedCity News.